000 03468nam a22003855i 4500
001 280344
003 MX-SnUAN
005 20160429154020.0
007 cr nn 008mamaa
008 150903s2010 xxu| o |||| 0|eng d
020 _a9780387692593
_99780387692593
024 7 _a10.1007/9780387692593
_2doi
035 _avtls000332012
039 9 _a201509030212
_bVLOAD
_c201404122008
_dVLOAD
_c201404091735
_dVLOAD
_y201402041018
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC254-282
100 1 _aNagarajan, Lalitha.
_eeditor.
_9305221
245 1 0 _aAcute Myelogenous Leukemia :
_bGenetics, Biology and Therapy /
_cedited by Lalitha Nagarajan.
250 _a1.
264 1 _aNew York, NY :
_bSpringer New York,
_c2010.
300 _aIx, 280 páginas
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aCancer Treatment and Research,
_x0927-3042 ;
_v145
500 _aSpringer eBooks
505 0 _aThe Leukemia Stem Cell -- Epigenetic Mechanisms in AML – A Target for Therapy -- Chromosomal Translocations in AML: Detection and Prognostic Significance -- Chromosomal Deletions in AML -- Genes Predictive of Outcome and Novel Molecular Classification Schemes in Adult Acute Myeloid Leukemia -- Receptor Tyrosine Kinase Alterations in AML – Biology and Therapy -- Lineage-Specific Transcription Factor Aberrations in AML -- Proleukemic RUNX1 and CBF? Mutations in the Pathogenesis of Acute Leukemia -- Acute Myeloid Leukemia with Mutated Nucleophosmin (NPM1): Molecular, Pathological, and Clinical Features -- MicroRNAs: New Players in AML Pathogenesis -- Murine Models of Human Acute Myeloid Leukemia -- Apoptosis in Leukemias: Regulation and Therapeutic Targeting -- Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy -- Immunotherapy of AML -- Therapy of Acute Myelogenous Leukemia in Adults.
520 _aAcute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered. "The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise." Steven T. Rosen, M.D. Series Editor
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9780387692579
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-0-387-69259-3
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c280344
_d280344